

Subject Index

- Acute myocardial infarction 53, 54, 63–91
 - β -adrenoreceptor blocking compounds
 - in 94, 97–100
 - analgesia 70–74
 - anti-arrhythmic drugs in 100
 - anticoagulant drugs in 104–106
 - arrhythmias 75
 - bed rest 74–75
 - bradyarrhythmias 76
 - cardiogenic shock in 83–88
 - clinical presentation 64–66
 - clinical studies on secondary prevention following 98
 - complete heart block 77
 - complications 75–89
 - complications from myocardial damage 78
 - differential diagnosis 66
 - enhanced anaerobic metabolism 80
 - enhanced transport of energy substrate to ischaemic myocardium 79
 - exercise in 109
 - first degree heart block 76
 - general management 70
 - hospital discharge 74–75
 - hospital phase 69
 - increased plasma osmolality 79
 - laboratory findings 66
 - management 67–70
 - myocardial oxygen delivery 80
 - opioid agonist/antagonist treatment 71
 - oxygen therapy in 75
 - platelet-active drugs in 106–109
 - prehospital phase 67–69
 - protection against local autolytic damage 79
 - reduction of myocardial oxygen consumption 78–79
 - rehabilitation 70
 - risk factor modification 109–115
 - second degree heart block 77
 - secondary prevention following 93–118
 - see also* Secondary prevention of acute myocardial infarction
 - secondary prevention trial design 93–98
 - signs 65
 - sinus bradycardia 76, 77
 - supraventricular tachycardia 77
 - symptoms 65
 - tachyarrhythmias 77
 - thrombolytic therapy 80–84
 - ventricular extrasystoles in 76
 - ventricular fibrillation 78
 - ventricular tachycardia 78
- Acute pulmonary oedema 158
- Adrenaline 60
- Adrenergic neurone blocking compounds 199–201
- α -Adrenoceptor blocking compounds
 - in cardiac failure 169
 - in hypertension 205–208
 - mechanism of action 205
 - subtypes 42–43
- β -Adrenoceptor blocking compounds 136–137, 146, 196
 - adverse effects 137, 198–199
 - ancillary properties of 44
 - cardioselectivity 45
 - central nervous system effects 197
 - choice of 47
 - classification of 199
 - clinical use 137, 197–198
 - compliance 48–49
 - haemodynamic factors 196
 - in acute myocardial infarction 78, 94, 98–100
 - in angina pectoris 42–49
 - in cardiac failure 165
 - in emergency or elective surgery 48

- in hypertension 182–187, 196–199
 - in hypertrophic cardiomyopathy 262, 263
 - intrinsic sympathomimetic activity 45
 - mechanism of action 137, 196–197
 - membrane-stabilising action 44
 - pharmacokinetic properties 45–47
 - properties of 200
 - side-effects 45, 47–48
- Adrenoceptor theories 42
- Afterload 153
- Afterload reduction 167, 232
- Alcohol ingestion 265
- Alcoholism 180
- Aldosterone 157
- Aldosterone antagonists in cardiac failure 163
- Amiloride in hypertension 191
- Aminophylline in acute left ventricular failure 170
- Amiodarone 147
 - adverse effects 139
 - clinical use 138
 - in hypertrophic cardiomyopathy 263
 - mechanism of action 138
 - pharmacokinetics 138
- Amoxicillin 250, 255
- Ampicillin 252
- Angina pectoris 29–52
 - clinical aspects of drug use 31–33
 - clinical presentation 29
 - clinical subsets 29
 - differential diagnosis 29
 - drug treatment in 35–52
 - exercise 34
 - general measures 33–34
 - investigations 30
 - management 31, 49–50
 - pain relief 34
 - pathophysiology 30
 - step care management 33
 - unstable 49–50, 121
- Angiotensin I 212
- Angiotensin II 212, 213
- Angiotensin converting enzyme (ACE)
inhibitors 212–214
- Anti-arrhythmic drugs 127
 - chemical structures 128
 - class I 129, 130–136
 - class II 130, 136–138
 - class III 130, 138–139
 - class IV 130, 139–140
 - classification of 128–130
 - for ventricular arrhythmias 148
 - ideal properties 127–128
 - in acute myocardial infarction 100
 - site of action 129
- Anticoagulants in acute myocardial infarction 104–106
 - drug interactions 12
 - during pregnancy 243
 - in cardiomyopathy 263, 267
 - mitral valve disease 229
 - pulmonary thromboembolism 276–278
- Antihypertensive drugs, drug interactions involving 11
- Aortic regurgitation 238–239
 - medical management 239
 - pathophysiology 238–239
 - prognosis 239
 - signs and typical investigative findings in 238
 - surgical management 239
- Aortic stenosis 235–238
 - clinical presentation 236
 - medical management 237
 - natural history 236
 - pathophysiology 236
 - signs and typical investigative findings 237
 - surgical management 237–238
- Aortic valve disease 235–239
- Arrhythmias. *See* Cardiac arrhythmias
- Arthritis 220
- Artificial valves 241–243
 - ball and cage valves 242
 - Bjork-Shiley valve 242
 - choice of valve 243
 - complications during pregnancy 243
 - haemodynamic properties 243
 - Lillehei-Kaster pivoting valve 242
 - mechanical prostheses 242
 - Smeloff-Cutter valve 242
 - tissue valves 242
- Artificial ventilation 58
- Aspirin
 - in acute myocardial infarction 106–108
 - in rheumatic fever 223
- Atenolol 48
 - in acute myocardial infarction 99
 - in hypertension 182, 183, 184, 186, 187
- Atherosclerosis 15–27, 29
 - femoral 21
- Atropine 60
- Barlow's syndrome 232
- Baroreceptors, resetting in 197
- Bendrofluzide 182, 196
- Bezafibrate 24
- Bile acid reabsorption 25
- Bile acid sequestrant resins 24–25
- Bioavailability of cardioactive drugs 4
- Blood pressure 175–177, 179
 - rapid lowering of 214–216
 - regulation of 181
 - see also* Hypertension
- Bretylum tosylate 137–138
- Bumetanide
 - in cardiac failure 163
 - in hypertension 190

- Calcium channel blockers 192
 examples of currently used 39
 haemodynamic effects 40
 in angina pectoris 38–42
 in hypertension 182, 186–187, 192–196
 in hypertrophic cardiomyopathy 263
 mechanism of action 39, 192–193
- Calcium chloride 60
- Captopril
 adverse effects 214
 clinical use 213
 in cardiac failure 169
 in hypertension 213–214
- Cardiac arrest 55–60
 diagnosis and treatment of arrhythmia 59
 drug list for 57
 equipment used in treatment of 56
 initial clinical assessment 58
 post-resuscitation aftercare 60
- Cardiac arrhythmias 125–150
 asystole 59
 atrial extrasystoles 142–143
 atrial fibrillation 143–144, 228
 atrial flutter 144–145
 atrial tachycardia 145–147
 diagnosis 140–141
 enhanced automaticity 125–127
 in acute myocardial infarction 76–79
 in hypertrophic cardiomyopathy 262
 in mitral valve prolapse 234
 mechanisms 125–127
 re-entrant mechanism 127
 sinus bradycardia 142
 sinus tachycardia 141–142
 treatment 141–149
- Cardiac catheterisation
 in acute myocardial infarction 81, 82
 in acute pulmonary embolism 275
 in angina pectoris 30
 in aortic regurgitation 238
 in aortic stenosis 237
 in cardiac failure 152, 160
 in cardiogenic shock 85, 86
 in congestive cardiomyopathy 266
 in hypertrophic cardiomyopathy 257, 258, 261
 in investigation of arrhythmias 141
 in mitral regurgitation 231
 in mitral stenosis 229
 in mitral valve prolapse 234
 in restrictive cardiomyopathy 268
 in tricuspid regurgitation 241
 in tricuspid stenosis 240
 in unstable angina 121
 in ventricular septal defect 120
- Cardiac enzyme wash-out 83
- Cardiac failure 9, 85, 88, 120, 144, 151–174
 causes of 154
 clinical syndrome of 151
 compensatory mechanisms 153–157
 cardiac 153–155
 extracardiac 155–157
 definition of 151
 diuretic therapy 162–164
 general supportive measures 161
 in hypertrophic cardiomyopathy 261–263
 investigations 159–160
 long-term management 169–170
 long-term oral therapy 168
 management 160–169
 parenteral therapy 168
 pathophysiology 153, 171
 precipitating factors 160–161
 problems and challenges 171–172
 specific antifailure therapy 162–169
 treatment 160
 treatment aims 161
 see also Left heart failure; Right heart failure
- Cardiac function, regulation of 151–153
- Cardiac glycosides 145, 146, 165–167, 170, 232
- Cardiac massage 58, 59
- Cardiac pacing 60
- Cardiogenic shock
 clinical signs 84
 diagnosis 56–58
 haemodynamic changes 85
 haemodynamic monitoring 86
 in acute myocardial infarction 83–88
 laboratory findings 84–85
 mechanical treatment 87
 treatment 85
- Cardiomyopathies 257–270
 classification 257
 definition 257
 obliterative 257
 see also Congestive cardiomyopathy
 Hypertrophic cardiomyopathy
 Restrictive cardiomyopathy
- Cardiopulmonary resuscitation 58–60
- Cardiostimulant drugs 60
- Cardioversion 147
- Carditis 220
- Catecholamines 42, 44, 86, 137, 165
- Centrally acting drugs 201–205
- Cephalosporin 163
- Chest pain, causes of 30, 66
- Chest X-ray
 in cardiac failure 159
 in congestive cardiomyopathy 266
- Cheyne-Stokes respiration 84
- Cholesterol levels 19–21, 25, 26
- Cholestyramine 21, 22, 24, 25
- Chorea 221
- Ciprofibrate 24
- Clofibrate 19–21, 23
 in acute myocardial infarction 111

- Clonidine
adverse effects 205
clinical use 204
in hypertension 183, 201, 204–205
mechanism of action 204
- Closed mitral valvotomy 230
- Colestipol 22, 24, 25
- Colifbrate 22
- Community emergency care systems 54–55
- Congestive cardiomyopathy 264–267
associations 265
cause of myocarditis 265
clinical presentation 264–265
complications 266
diagnosis 265
investigations 266
pathophysiology 264
prognosis 267
signs 265
symptoms 264
treatment 266–267
- Contractility 152
- Cor pulmonale 271–280
acute exacerbation 272–273
aetiology 271
long-term management 273
symptoms and signs 272
treatment 272–273
- Coronary artery anatomy 63–64
- Coronary artery bypass surgery 123
- Coronary artery thrombus 80, 104
- Coronary heart disease (CHD) 26, 53, 265
death rate 15
high risk 20
incidence 15, 19–21
indications for surgery 119–124
pathophysiology 15
primary prevention 20
risk factors 16, 19
- Coronary spasm 31, 32, 50
- Corticosteroids 60, 224
- Coxiella* 253
- Creatinine clearance 7
- Culture-negative endocarditis 253–254
- Desensitisation 43
- Dexamethasone 60
- Diamorphine in acute myocardial infarction 73
- Diazoxide
clinical use 215
in hypertension 185, 214–216
- Digitalis toxicity 166–167
- Digitoxin 8, 166
- Digoxin 145, 166, 263
- Diltiazem in angina pectoris 41–42
- Direct current cardioversion 144
- Disopyramide 132–133, 146
adverse effects 133
clinical use 132
in acute myocardial infarction 100
in hypertrophic cardiomyopathy 263
pharmacokinetics 132
- Diuretics 232
classification 188
in cardiac failure 263
in hypertension 182, 183, 186–191
mechanism of action 188
see also Loop diuretics
- Dobutamine
in cardiac failure 165
in cardiogenic shock 86
- Dopamine
in cardiac failure 165
in cardiogenic shock 86
- Down regulation 44
- Drug absorption 2–4
interactions affecting 13
- Drug administration
chronic 8–9
intramuscular 3–4
intravenous 3
oral 2–3
parenteral 3–4
subcutaneous 4
- Drug bioavailability 4
- Drug biotransformation 7
- Drug disposition, influence or organ disease 9–10
- Drug distribution 4–6
interactions affecting 13
- Drug elimination 6–7
- Drug excretion 7–8
interactions involved in 13
- Drug half-life 6
- Drug interactions 10–13
affecting absorption 13
affecting distribution 13
affecting metabolism 13
involved in excretion 13
involving β -adrenoreceptor blocking drugs 11
involving aldosterone antagonists 12
involving anti-arrhythmic drugs 10
involving cardiac glycosides 11
involving diuretics 12
involving oral anticoagulants 12
pharmacodynamic 1, 10
pharmacokinetic 1, 12
- Drug metabolism, drug interactions
affecting 13
- Drug monitoring 6, 128
- Drug pharmacodynamics 1, 10
- Drug pharmacokinetics 1, 12
- Drug properties 1–14
- Drug treatment 20, 21
in angina pectoris 35–52

- in cardiac arrest 57, 59
- see also* under specific drugs and specific conditions
- Dyspnoea
 - in left heart failure 157
 - in mitral stenosis 228
- Echocardiography
 - in cardiac failure 159–160
 - in congestive cardiomyopathy 266
 - in mitral valve prolapse 234
 - in rheumatic fever 222
 - in rheumatic heart disease 229, 231, 237, 238, 240, 241
- Electrocardiography 30, 82
 - in cardiac failure 159
 - in congestive cardiomyopathy 266
- Enalapril 169, 213
- Endocarditis
 - acute 246
 - culture-negative 253–254
 - due to gram-negative bacilli 253
 - enterococcal 252
 - infective. *See* Infective endocarditis
 - penicillin-sensitive 250–251
 - subacute 246
 - staphylococcal infective 251–252
- Erythema marginatum 221
- Erythromycin 225, 251
- Ethacrynic acid in hypertension 191
- Exertional fatigue and weakness 158

- First pass metabolism 3
- Flecainide 135–136
 - adverse effects 136
 - clinical use 136
 - pharmacokinetics 136
- Frank-Starling mechanism 155
- Frusemide 87
 - in acute left ventricular failure 170
 - in cardiac failure 163
 - in hypertension 190

- Ganglion blocking compounds 199–201
- Gemfibrozol 24
- Glyceryl trinitrate (GTN) 35, 36
- Glycine xylidide (GX) 133
- Gynaecomastia 191

- Haemoptysis 228
- Heart block
 - complete 77
 - first degree 76
 - second degree 77
- Heparin
 - in acute myocardial infarction 89
 - in pulmonary thromboembolism 276
 - side-effects 276–277
- Hepatic blood flow 2
- Hepatic clearance 3
- Hepatic metabolism 3
- Hepatic microsomal system 7
- High density lipoprotein (HDL) 16, 18, 24, 25
- Hydralazine 7
 - adverse effects 210
 - clinical use 210
 - in cardiac failure 169
 - in hypertension 183, 187, 209–210
 - mechanism of action 209
 - pharmacokinetics 210
- Hyperglycaemia 162
- Hyperkalaemia 191
- Hyperlipoproteinaemia 15–27
 - clinical associations of 19–21
 - management of 21–23
 - metabolic defects in 18–19
 - treatment of 26
 - type I 18, 21
 - type II 18
 - type IIA 21
 - type IIB 22
 - type III 18, 22
 - type IV 19, 23
 - type V 19, 23
- Hypertension 175–218
 - accelerated phase 184
 - aetiology 175–176
 - alcohol intake 180
 - general management 179–185
 - hydrochlorothiazide 182
 - indapamide 190
 - in elderly 185–187
 - in pregnancy 187–188
 - investigations 178–179
 - malignant 184
 - mild 178, 181–182
 - moderate 182–184
 - nifedipine in 192–194
 - non-pharmacological treatment
 - methods 179–180
 - parenteral medication 184–185
 - parenteral therapy 214–216
 - pharmacological treatment methods 180–185
 - pindolol 182
 - prognosis 176–177
 - relaxation techniques 180
 - risk factors 176–177, 180
 - salt restriction 180
 - severe 184
 - specific anti-hypertensive therapy 188–214
 - therapeutic trials 178
 - treatment aims 179

- treatment benefits 177–178
- treatment criteria 175
- verapamil in 192–194
- weight reduction 179
- xipamide 190
- Hypertrophic cardiomyopathy 257–264
 - clinical presentation 259–260
 - general symptoms and arrhythmias 263
 - haemodynamic changes 258–259
 - investigations 260–261
 - medical measures 263
 - pathophysiology 257–258
 - prognosis and complications 261–262
 - signs 260
 - surgical management 264
 - symptoms 259–269
 - treatment 262–264
- Hypokalaemia 162, 163
- Indoramin
 - adverse effects 207
 - clinical use 207
 - in hypertension 207
 - pharmacokinetics 207
- Infective endocarditis 245–255
 - clinical presentation 245–246
 - complications 246–247
 - diagnosis 247
 - enterococcal endocarditis 252
 - Gram-negative bacilli 253
 - haemophilus infections 253
 - management 247–249
 - pathophysiology 245
 - prophylaxis 254–255
 - range of infection 249
 - Staphylococcus* 247
 - Staphylococcus aureus* 251
 - Staphylococcus epidermidis* 247
 - Streptococcus* 247
 - Streptococcus viridans* 81–84, 250, 251
- Intermediate density lipoprotein (IDL) 16, 18, 19
- Isoprenaline 60
- Isosorbide dinitrate 36–38
- Labetalol
 - adverse effects 208
 - clinical use 208
 - in hypertension 183, 208
 - pharmacokinetics 208
- Left heart catheterisation 160
- Left main coronary disease 121
- Left ventricular ejection time (LVET) 38
- Left ventricular failure
 - symptoms and signs 157–158
 - treatment 170–171
- Lignocaine 3, 133–134
 - adverse effects 134
 - clinical use 133
 - in acute myocardial infarction 103
 - pharmacokinetics 133–134
- Lipid-lowering drugs 23–26, 109–114
- Lipoprotein classes 16
- Lipoprotein metabolism 16–17
- Lipoprotein transport in man 17
- Loop diuretics
 - adverse effects 191
 - examples of 189
 - in acute left ventricular failure 170
 - in cardiac failure 162–163
 - in hypertension 190–191
- Low density lipoprotein (LDL) 16, 18, 24–26
- Medic One advanced life support system 54
- Methyldopa
 - adverse effects 203–204
 - clinical use 203
 - in hypertension 183, 187, 201, 202–204
 - pharmacokinetics 202–203
- Metroprolol 48
 - in acute myocardial infarction 99
 - in hypertension 182, 183, 186, 187
- Mexiletine 134–135
 - adverse effects 134–135
 - clinical use 134
 - pharmacokinetics 134
- Minoxidil
 - administration 211
 - adverse effects 211
 - clinical use 211
 - in hypertension 211
 - pharmacokinetics 211
- Mitral regurgitation 120–121, 230–232
 - clinical presentation 231
 - medical management 232
 - natural history 231–232
 - pathophysiology 231
 - surgical management 232
- Mitral stenosis 227–230
 - clinical presentation 228
 - medical management 229
 - natural history 228
 - pathophysiology 227–228
 - signs and investigative findings in 229
 - surgical management 229–230
- Mitral valve disease 227–235
- Mitral valve prolapse 232–235
 - clinical presentation 233
 - complications 234
 - conditions associated with or causing 233
 - investigations 234
 - management 235
 - pathophysiology 233
 - signs and typical investigative findings 234

- Mitral valve replacement 230
Mobitz type II heart block 77
Monoethyl glycine xylidide (MEGX) 133
Morphine
 cardiovascular effects 72
 gastrointestinal effects 72–73
 in acute left ventricular failure 170
 in acute myocardial infarction 70–73
 respiratory effects 72
Myocardial blood flow 32
Myocardial infarction, acute. *See* Acute myocardial infarction
Myocardial necrosis 63
Myocardial oxygen demand 30;
- Nadolol 48
Neurotransmitter release 197
Nicotinic acid 23, 24
Nicrofuranose 22
Nifedipine 50
 adverse effects 194
 clinical use 193–194
 in angina pectoris 40–41
 in hypertension 182, 183, 185, 192–194
 retard formulation 194
Nitrates
 clinical pharmacology 36–38
 currently used preparations 37
 in acute myocardial infarction 79
 in angina pectoris 35–38, 49
 in cardiac failure 168
 in cardiogenic shock 87
 in pain relief 32
 intravenous 38
 longer acting 36, 37
 side effects 36
Nitroglycerine 38
Nitroprusside
 clinical use 215–216
 in cardiogenic shock 87
 in hypertension 185, 215–216
 mechanism of action 215
Normotensive shock 85
Norverapamil 140
- Open valvotomy 230
Orthopnoea in left heart failure 157
Ouabain in cardiac failure 166
Oxprenolol 48
 in hypertension 187
Oxygen consumption, reduction of myocardial 78–79
Oxygen supply and demand 30
Oxygen therapy
 in acute myocardial infarction 75
 in cor pulmonale 272–273
 in pulmonary thromboembolism 278
- Pain relief 32, 34, 82, 85
Paroxysmal nocturnal dyspnoea 157
Penicillin 225, 250, 251, 252, 254, 255
Penicillin-sensitive endocarditis 250–251
 length of treatment 250–251
 route of administration 250
Pentazocine in acute myocardial infarction 73
Perhexilene in angina pectoris 42
Phenoxybenzamine in hypertension 205
Phentolamine
 in cardiogenic shock 87
 in hypertension 205
Plasma renin activity (PRA) 197
Platelet-active drugs in acute myocardial infarction 106–109
Platelet-derived growth factor (PDGF) 15
Positive inotropes in cardiac failure 164
Potassium-sparing diuretics in hypertension 191
Prazasin
 adverse effects 207
 clinical use 207
 in cardiac failure 169
 in hypertension 184, 205–207
 pharmacokinetics 206
Pregnancy
 congestive cardiomyopathy in 265
 hypertension in 187–188
 prosthetic valve complications 243
Preload 152
Preload reduction 167, 171
Prenalterol in cardiac failure 165
Presynaptic receptors 197
Probucol 22, 25
Procainamide 7, 131–132, 146
 adverse effects 132
 clinical use 131
 in acute myocardial infarction 100
 pharmacokinetics 131–132
Propranolol 2, 48
 in acute myocardial infarction 99
 in hypertension 182–184, 196–198
Prostacyclin 108
Prostaglandin synthesis 108
Prosthetic valves 242
Protein binding 9–10
Pulmonary heart disease. *See* Cor pulmonale
Pulmonary hypertension 228
Pulmonary oedema, treatment of 170–171
Pulmonary thromboembolism 273–279
 anticoagulant therapy 276
 clinical presentation 274
 long-term prognosis 279
 management 275–279
 pathophysiology 273–274
 prophylaxis 275
 surgical management 279

- Pump failure
 diagnosis 84
 evidence of early 85
- Quinidine 130–131, 146
 adverse effects 131
 clinical use 130–131
 in acute myocardial infarction 100
 pharmacokinetics 130–131
- Radioligands 43
- Renal disease 9
- Renin-angiotensin-aldosterone system 155, 212
- Reserpine
 adverse effects 202
 clinical use 202
 in hypertension 201
- Restrictive cardiomyopathy 267–268
 clinical presentation 268
 haemodynamics 268
 investigations 268
 management 268
 pathophysiology 267
 signs 268
 symptoms 268
- Resuscitation techniques 54
- Rheumatic fever 219–225
 antibiotic therapy 224
 antirheumatic therapy 222–224
 clinical findings 222
 clinical presentation 221–222
 diagnosis 222
 general management 222
 laboratory investigations 222
 long-term prophylaxis 224–225
 major features 221–222
 minor features 221
 myocarditis in 219–220
 pathology 219
 treatment 222–225
- Rheumatic heart disease 240
- Right heart catheterisation 160
- Right heart failure, symptoms and signs of 159
- Salicylates
 general pharmacology 223
 in rheumatic fever 223
- Secondary prevention of acute myocardial infarction
 dextrothyroxine 111
 dietary intervention in 114–115
 dipyridamole 109
 exercise 34, 109
 nicotinic acid 114
 oestrogen therapy 111
 practolol 99
 sulfinpyrazone 108–109
- Sodium bicarbonate 59
- Sodium nitroprusside 193, 215–216
- Sotalol 48
- Specific heart muscle disease 258
- Spirololactone
 in cardiac failure 163
 in hypertension 191
- Streptococcal infection 224
- Straphylococcal infective endocarditis 251–252
- Streptokinase in pulmonary thromboembolism 278
- Streptomycin 250
- Stroke volume determinants 151–153
- Subcutaneous nodules 221
- Sudden death 53–61
 in hypertrophic cardiomyopathy 262
- Supersensitivity 44
- Surgery in coronary heart disease 119–124
- Swan-Ganz catheter 86
- Sympathetic nervous activity 155
- Symptomatic femoral atherosclerosis 27
- Systemic embolisation 228
- Tachyphylaxis 43
- Thiazide diuretics
 adverse effects 189
 in cardiac failure 162
 in hypertension 182, 189
- Thromboembolism 88–89
- Thrombolytic therapy 278
 in acute myocardial infarction 81–84
 in pulmonary thromboembolism 278
- Thrombosis 88–89
- Thromboxane A₂ 108
- Thromboxane synthesis 100
- Thromboxane synthetase 33
- Tocainide
 adverse effects 135
 clinical use 135
 pharmacokinetics 135
- Tolerance 43
- Total body clearance 8
- Transvenous endomyocardial biopsy in congestive cardiomyopathy 266
- Triamterene in hypertension 191
- Tricuspid regurgitation 240–241
 clinical presentation 241
 management 241
 signs and typical investigative findings in 241
- Tricuspid stenosis 239–240
 clinical presentation 240
 management 240
 signs and typical investigative findings 240

-
- Tricuspid valve disease 239–241
Triglyceride 23, 24, 26
- Up regulation 44
- Uric acid excretion 162
- Urokinase in pulmonary thromboembolism 279
- Valvular disease 227–244
- Vancomycin 251
- Vasodilators
 in cardiac failure 167–169
 in hypertension 209–212
- Venous cannulation 59
- Ventricular aneurysm 123–124
- Ventricular arrhythmias, anti-arrhythmic drugs for 148
- Ventricular dilatation 155
- Ventricular extrasystoles 147–148
 in acute myocardial infarction 76
- Ventricular fibrillation 53, 54, 59, 93
 in acute myocardial infarction 78
 long-term management 55
 prognosis 55
- Ventricular hypertrophy 155
- Ventricular septal defects 119–120
- Ventricular tachycardia 148–149
 in acute myocardial infarction 78
- Verapamil 50, 139–140, 146
 adverse effects 140, 195–196
 clinical use 139, 195
 in angina pectoris 41
 in hypertension 182, 192–196
 mechanism of action 139
 pharmacokinetics 140
- Very low density lipoprotein (VLDL) 16, 18, 19, 23, 24
- Volume of distribution 6
- Warfarin in pulmonary thromboembolism 277
- Wenckebach type heart block 77
- Xanthomata 22